Fennec Pharmaceuticals Inc.FENCNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Year-over-year research & development expense growth
Latest
-72.90%
↓ 150% below average
Average (39q)
144.85%
Historical baseline
Range
High:5133.33%
Low:-96.58%
CAGR
+3.5%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -72.90% |
| Q2 2025 | 13.83% |
| Q1 2025 | 88.00% |
| Q4 2024 | -48.45% |
| Q3 2024 | -38.22% |
| Q2 2024 | 5133.33% |
| Q1 2024 | -90.88% |
| Q4 2023 | 174.03% |
| Q3 2023 | 48.05% |
| Q2 2023 | 102.64% |
| Q1 2023 | -96.58% |
| Q4 2022 | -85.35% |
| Q3 2022 | -28.79% |
| Q2 2022 | -22.91% |
| Q1 2022 | 179.08% |
| Q4 2021 | -57.74% |
| Q3 2021 | 55.51% |
| Q2 2021 | -67.41% |
| Q1 2021 | 99.02% |
| Q4 2020 | -10.38% |
| Q3 2020 | 19.68% |
| Q2 2020 | -13.38% |
| Q1 2020 | 10.34% |
| Q4 2019 | 50.07% |
| Q3 2019 | -59.62% |
| Q2 2019 | 17.83% |
| Q1 2019 | -3.02% |
| Q4 2018 | -4.17% |
| Q3 2018 | 125.31% |
| Q2 2018 | 15.82% |
| Q1 2018 | -22.23% |
| Q4 2017 | 80.08% |
| Q3 2017 | 47.75% |
| Q2 2017 | 48.00% |
| Q1 2017 | 29.31% |
| Q4 2016 | 55.36% |
| Q3 2016 | -19.42% |
| Q2 2016 | 195.74% |
| Q1 2016 | -33.80% |
| Q4 2015 | -19.32% |